ADVERTISEMENT
As mentioned, CAR-T therapies are usually used to treat blood cancers, but this study shows its potential for treating solid tumors.
While this gives hope to people with these conditions, it is worth noting that this was a small study of three patients, and more research is needed before the treatment is rolled out more widely for solid tumors.
Study co-author Elizabeth Gerstner, MD, a neuro-oncologist in the Department of Neurology at Massachusetts General Hospital, said: “We report a dramatic and rapid response in these three patients. Our work to date shows signs that we are making progress, but there is more to do.”
Marcela Maus, MD, PhD, director of the Cellular Immunotherapy Program agreed, and said: “These results are exciting, but they are also just the beginning – they tell us that we are on the right track in pursuing a therapy that has the potential to change the outlook for this intractable disease. We haven’t cured patients yet, but that is our audacious goal.”
